Severe periorbital edema secondary to STI571 (Gleevec)

Bita Esmaeli, Victor G. Prieto, Charles E. Butler, Stella K. Kim, M. Amir Ahmadi, Hagop M. Kantarjian, Moshe Talpaz

Research output: Contribution to journalArticlepeer-review

97 Scopus citations

Abstract

STI571 (imatinib mesylate; Gleevec) is a selective inhibitor of the bcr-abl, c-kit, and platelet-derived growth factor receptor tyrosine kinases. Mild periorbital edema has been noted as a common side effect in Phase I and II trials of this drug for the treatment of patients with chronic myelogenous leukemia and gastrointestinal stromal tumors. The authors report the case of male patient age 63 years who developed severe periorbital edema after treatment with STI571 for chronic myelogenous leukemia. His edema was severe enough to cause visual obstruction due to lower eyelid festoons that ultimately required surgical debulking. Histopathologic analysis of specimens of the excised upper and lower eyelid tissue revealed dermal dendrocytes that expressed the platelet-derived growth factor receptor and c-kit tyrosine kinases, suggesting a possible role for dermal dendrocytes in the development of this toxic effect.

Original languageEnglish (US)
Pages (from-to)881-887
Number of pages7
JournalCancer
Volume95
Issue number4
DOIs
StatePublished - Aug 15 2002

Keywords

  • Periorbital edema
  • STI571
  • Surgical debulking
  • Tyrosine kinases

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint

Dive into the research topics of 'Severe periorbital edema secondary to STI571 (Gleevec)'. Together they form a unique fingerprint.

Cite this